Introduction

Pulmonary fibrosis is a progressive interstitial lung disease characterized by the deposition of scar tissue in the lung parenchyma, leading to irreversible loss of respiratory function. The condition encompasses a group of disorders, with idiopathic pulmonary fibrosis (IPF) being the most common and lethal form. Despite advances in pharmacotherapy, the median survival after diagnosis remains only 3–5 years, underscoring the critical need for early detection and accurate monitoring of disease progression. Medical imaging, particularly high-resolution computed tomography (HRCT), has become the cornerstone of diagnosis and surveillance. However, visual interpretation of HRCT images is subjective and prone to variability. Over the past decade, image processing technologies have emerged as powerful tools to enhance the objectivity, reproducibility, and precision of fibrosis assessment. This article explores the application of image processing techniques—from classical segmentation to modern deep learning—in detecting and monitoring pulmonary fibrosis, highlighting their clinical utility, current limitations, and future promise.

Understanding Pulmonary Fibrosis and Its Clinical Burden

Pulmonary fibrosis refers to a spectrum of diseases in which the lung interstitium becomes thickened by excessive extracellular matrix deposition. The most common form, IPF, typically affects older adults and presents with progressive dyspnea, dry cough, and exercise limitation. The pathogenesis involves repetitive alveolar epithelial injury followed by aberrant wound healing, leading to fibroblast proliferation and collagen accumulation. As fibrosis advances, gas exchange becomes impaired, resulting in hypoxemia and eventual respiratory failure. The clinical course is variable: some patients experience rapid decline, while others remain stable for years. Accurate staging and longitudinal monitoring are essential for prognostication, treatment decisions, and clinical trial enrollment. Currently, pulmonary function tests (PFTs) and HRCT are the primary tools for assessment, but PFTs often lack sensitivity to early changes and may not correlate well with structural damage. HRCT provides detailed anatomical information, yet subjective interpretation limits its reliability. This is where computational image analysis offers transformative potential.

The Critical Role of High-Resolution Computed Tomography

HRCT is the imaging modality of choice for evaluating diffuse parenchymal lung diseases. With thin-section slices (1–1.5 mm) and high spatial frequency reconstruction algorithms, HRCT can visualize fine anatomical details such as interlobular septa, secondary pulmonary lobules, and ground-glass opacities. In pulmonary fibrosis, characteristic HRCT patterns include honeycombing (clustered cystic airspaces), traction bronchiectasis, and reticulation. The presence and extent of honeycombing are key diagnostic criteria for IPF and strong predictors of mortality. However, radiologists must subjectively assess the pattern, distribution, and severity, leading to significant inter- and intra-reader variability. Moreover, subtle fibrotic changes may be missed in early disease. Image processing aims to quantify these features objectively, enabling consistent measurements across time points and observers. Techniques such as histogram analysis, texture-based classification, and machine learning have been applied to HRCT data to extract biomarkers of fibrosis severity and progression.

Core Image Processing Techniques Applied to Pulmonary Fibrosis

Segmentation of Fibrotic Regions

Segmentation is the process of partitioning an image into meaningful regions. In pulmonary fibrosis, the goal is to isolate areas of lung parenchyma affected by fibrosis from normal tissue, as well as from other structures like airways and vessels. Manual segmentation by radiologists is time-consuming and impractical for large datasets. Automated segmentation algorithms use thresholding, region-growing, or more advanced techniques such as active contours and convolutional neural networks (CNNs). For example, U-Net architectures have been successfully trained to segment honeycombing and reticulation patterns on HRCT slices. Accurate segmentation enables volumetric quantification of fibrotic burden, which can be tracked longitudinally to assess disease progression or response to therapy. Challenges include the heterogeneity of fibrotic patterns and the presence of confounders like emphysema or pneumonia.

Texture Analysis for Tissue Characterization

Texture analysis quantifies the spatial arrangement of pixel intensities and provides numerical descriptors of tissue patterns. In HRCT, fibrotic tissues exhibit characteristic textures—such as coarse reticular or honeycomb patterns—that differ from normal lung or emphysematous regions. First-order statistics (mean, variance, skewness) capture overall density, while second-order statistics (e.g., co-occurrence matrices) describe spatial relationships. Higher-order methods like fractal analysis and wavelet transforms can capture multiscale features. Texture features have been used to classify regions as normal, ground-glass, reticular, or honeycomb, with accuracies exceeding 85% in some studies. These features can also be aggregated into a “fibrosis score” that correlates with clinical outcomes like forced vital capacity (FVC) decline and mortality. Texture analysis provides a reproducible, quantitative alternative to visual scoring systems such as the Warrick score or the ILD–gender–age–physiology (GAP) index.

Machine Learning and Deep Learning Classifiers

Machine learning (ML) algorithms, including support vector machines, random forests, and gradient boosting, have been applied to combine texture features and clinical variables for disease classification and prognosis prediction. However, deep learning (DL) methods—particularly CNNs—have surpassed classical ML in many medical imaging tasks. CNNs can learn hierarchical features directly from raw image patches without manual feature engineering. For pulmonary fibrosis, DL models have been developed to detect the presence of fibrosis, quantify its extent, and predict FVC decline. Some models integrate clinical data (age, sex, lung function) with imaging features to improve accuracy. Transfer learning using pre-trained networks (e.g., ResNet or DenseNet) on large natural image datasets can mitigate the scarcity of annotated medical images. Recent work by Walsh et al. demonstrated that a deep learning algorithm could classify IPF from other interstitial lung diseases on HRCT with an area under the curve (AUC) of 0.94. Such models promise to assist radiologists by flagging suspicious regions and providing second-opinion assessments.

Quantitative Imaging Biomarkers

Quantitative imaging biomarkers (QIBs) are objective measures extracted from medical images that reflect underlying pathophysiology. For pulmonary fibrosis, QIBs include lung volume, mean lung density, histogram percentiles (e.g., 15th percentile density), and texture-based fibrosis scores. The “quantitative lung fibrosis” (QLF) score, derived from adaptive texture analysis, has been validated as a predictor of mortality independent of PFTs. Other biomarkers, such as the extent of traction bronchiectasis or honeycombing volume, can be computed automatically. Longitudinal changes in QIBs can be tracked with high precision, often detecting progression earlier than FVC changes. For example, a 5% increase in the extent of fibrosis on HRCT may precede a 10% decline in FVC by several months. Regulatory agencies, including the FDA, have recognized the value of QIBs as surrogate endpoints in clinical trials, accelerating the development of anti-fibrotic therapies.

Clinical Applications and Benefits

Early Detection and Diagnosis

Early diagnosis of pulmonary fibrosis is critical because anti-fibrotic drugs like pirfenidone and nintedanib are most effective when initiated before extensive lung damage occurs. Image processing can identify subtle fibrotic changes—such as early reticulation or mild traction bronchiectasis—that may be overlooked by the human eye. Automated screening tools applied to chest CT scans performed for other indications (e.g., lung cancer screening) could flag at-risk patients for further evaluation. Moreover, texture-based classifiers can help differentiate IPF from other interstitial lung diseases (e.g., hypersensitivity pneumonitis or connective tissue disease–associated ILD), which require different management strategies. By reducing diagnostic delay, image processing can improve patient outcomes and potentially slow disease progression.

Monitoring Disease Progression and Treatment Response

Serial HRCT scans are increasingly used to monitor disease progression in clinical practice and trials. However, visual comparison of scans over time is challenging and prone to bias. Quantitative image processing provides objective metrics for change assessment. For instance, the annual change in the QLF score or the volume of honeycombing can be computed with high reproducibility. In the INPULSIS trials of nintedanib, a QIB-based analysis showed a slower rate of decline in lung density in the treatment arm compared to placebo, supporting the drug’s efficacy. Image processing also enables pixel-level mapping of change, showing which regions have worsened or improved. This capability can guide decisions about continuing or changing therapy and may serve as a surrogate endpoint in early-phase drug development. Additionally, AI-based tools can automatically compare HRCT scans from different time points, aligning anatomy and quantifying regional change.

Reducing Inter-Observer Variability

A major limitation of visual HRCT interpretation is inter-observer variability. Even among expert thoracic radiologists, agreement on the extent of fibrosis can be moderate (kappa values 0.4–0.6). Automated image analysis eliminates this variability by applying consistent algorithms. This is particularly important for multicenter clinical trials where scans are read at different sites. Quantitative endpoints derived from image processing have been shown to be more reproducible than visual scores, increasing statistical power and reducing sample size requirements. For routine clinical care, automated reports can provide standardized fibrosis metrics that aid communication between radiologists and pulmonologists, ensuring consistent disease severity assessment across visits and institutions.

Supporting Personalized Medicine

Pulmonary fibrosis exhibits significant heterogeneity in disease behavior and treatment response. Image processing can help stratify patients into subgroups based on imaging phenotype. For example, patients with a predominantly ground-glass pattern may have a better prognosis than those with extensive honeycombing. Texture analysis can also identify “high-risk” features—such as coarse reticulation or subpleural distribution—that correlate with rapid progression. By integrating imaging biomarkers with genomic and proteomic data, clinicians can develop personalized management plans. In the future, AI models could predict an individual patient’s trajectory and recommend the most effective therapy, moving beyond the current one-size-fits-all approach.

Current Challenges in Image Processing for Pulmonary Fibrosis

Despite promising results, several barriers hinder the widespread adoption of image processing in pulmonary fibrosis. First, the lack of standardized imaging protocols across institutions affects algorithm performance. Variations in slice thickness, reconstruction kernel, and radiation dose can alter texture features and introduce bias. Harmonization techniques, including intensity normalization and domain adaptation, are being developed but are not yet routine. Second, most algorithms are trained on datasets from single centers or specific scanner manufacturers, limiting generalizability. External validation in diverse populations and imaging settings is essential before clinical deployment. Third, the annotation of fibrotic regions for training deep learning models is labor-intensive and requires expert consensus. Unsupervised or semi-supervised learning approaches may alleviate this bottleneck, but they are still under investigation. Fourth, regulatory and reimbursement pathways for AI-based imaging tools remain unclear. Only a handful of products have received FDA clearance for ILD applications. Finally, integration into clinical workflows—such as picture archiving and communication systems (PACS)—and acceptance by radiologists require user-friendly interfaces and evidence of improved patient outcomes. Physician education and trust in algorithmic outputs are ongoing challenges.

Future Directions: AI Integration and Automated Workflows

The next frontier in image processing for pulmonary fibrosis lies in fully automated, end-to-end analysis pipelines that integrate imaging with clinical and molecular data. Advances in deep learning, particularly 3D CNNs and transformers, will enable volumetric analysis of the entire lung, capturing spatial relationships and disease burden more accurately than slice-by-slice methods. Multimodal AI models that combine HRCT, PFTs, demographic data, and genomic markers could predict individual disease trajectories with high precision. Longitudinal modeling using recurrent neural networks or temporal attention mechanisms may forecast future fibrotic progression based on historical imaging sequences. Additionally, explainable AI techniques—such as saliency maps and attention heatmaps—will help clinicians understand model reasoning and build trust. On the technical side, federated learning allows multiple institutions to collaboratively train models without sharing patient data, addressing privacy concerns and improving generalizability. Automated quality control algorithms can detect image artifacts or acquisition errors before analysis. As these technologies mature, we foresee a future where every HRCT scan for suspected fibrosis is automatically processed to generate a quantitative report—including fibrosis volume, subtype classification, and progression risk—integrated seamlessly into the electronic health record. Such tools will not replace radiologists but will augment their capabilities, freeing them to focus on complex diagnostic dilemmas and patient communication.

Conclusion

Image processing has transformed the detection and monitoring of pulmonary fibrosis, offering objective, reproducible, and sensitive tools that complement visual interpretation. From segmentation and texture analysis to machine learning and deep learning, these techniques enable early detection, accurate staging, and longitudinal tracking of fibrotic lung disease. They reduce inter-observer variability, support personalized treatment strategies, and provide quantitative endpoints for clinical trials. However, challenges remain in standardization, generalizability, annotation burden, and clinical integration. Continued collaboration among radiologists, pulmonologists, computer scientists, and regulatory bodies will be essential to translate these advances into routine practice. As AI and data-driven approaches evolve, image processing will play an increasingly central role in improving outcomes for patients with pulmonary fibrosis—a disease that demands precision, timeliness, and innovation.

External References